Eintrag weiter verarbeiten
Galectin-3 In Obesity And Type 2 Diabetes
Gespeichert in:
| Zeitschriftentitel: | Serbian Journal of Experimental and Clinical Research |
|---|---|
| Personen und Körperschaften: | |
| In: | Serbian Journal of Experimental and Clinical Research, 16, 2015, 4, S. 273-280 |
| Format: | E-Article |
| Sprache: | Unbestimmt |
| veröffentlicht: |
Walter de Gruyter GmbH
|
| Schlagwörter: |
| author_facet |
Pejnovic, Nada Pejnovic, Nada |
|---|---|
| author |
Pejnovic, Nada |
| spellingShingle |
Pejnovic, Nada Serbian Journal of Experimental and Clinical Research Galectin-3 In Obesity And Type 2 Diabetes General Medicine |
| author_sort |
pejnovic, nada |
| spelling |
Pejnovic, Nada 1820-8665 2335-075X Walter de Gruyter GmbH General Medicine http://dx.doi.org/10.1515/sjecr-2015-0057 <jats:title>Abstract</jats:title><jats:p>Galectin-3 is an important regulator of inflammation and acts as a receptor for advanced-glycation (AGE) and lipoxidation end-products (ALE). Evidence indicates a significant upregulation in circulating levels and visceral adipose tissue production of Galectin-3 in obesity and type 2 diabetes. Recent studies demonstrate development of obesity and dysregulation of glucose metabolism in Galectin-3 “knockout” (KO) mice, which also develop accelerated and more severe pathology in models of atherosclerosis and metabolically-induced kidney damage. Thus, evidence that Galectin-3 is an important player in metabolic disease is accumulating. This review discusses current evidence on the connection between Galectin-3 and metabolic disease, focusing on mechanisms by which this galectin modulates adiposity, glucose metabolism and obesity-associated inflammatory responses.</jats:p> Galectin-3 In Obesity And Type 2 Diabetes Serbian Journal of Experimental and Clinical Research |
| doi_str_mv |
10.1515/sjecr-2015-0057 |
| facet_avail |
Online Free |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTUxNS9zamVjci0yMDE1LTAwNTc |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTUxNS9zamVjci0yMDE1LTAwNTc |
| institution |
DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 |
| imprint |
Walter de Gruyter GmbH, 2015 |
| imprint_str_mv |
Walter de Gruyter GmbH, 2015 |
| issn |
1820-8665 2335-075X |
| issn_str_mv |
1820-8665 2335-075X |
| language |
Undetermined |
| mega_collection |
Walter de Gruyter GmbH (CrossRef) |
| match_str |
pejnovic2015galectin3inobesityandtype2diabetes |
| publishDateSort |
2015 |
| publisher |
Walter de Gruyter GmbH |
| recordtype |
ai |
| record_format |
ai |
| series |
Serbian Journal of Experimental and Clinical Research |
| source_id |
49 |
| title |
Galectin-3 In Obesity And Type 2 Diabetes |
| title_unstemmed |
Galectin-3 In Obesity And Type 2 Diabetes |
| title_full |
Galectin-3 In Obesity And Type 2 Diabetes |
| title_fullStr |
Galectin-3 In Obesity And Type 2 Diabetes |
| title_full_unstemmed |
Galectin-3 In Obesity And Type 2 Diabetes |
| title_short |
Galectin-3 In Obesity And Type 2 Diabetes |
| title_sort |
galectin-3 in obesity and type 2 diabetes |
| topic |
General Medicine |
| url |
http://dx.doi.org/10.1515/sjecr-2015-0057 |
| publishDate |
2015 |
| physical |
273-280 |
| description |
<jats:title>Abstract</jats:title><jats:p>Galectin-3 is an important regulator of inflammation and acts as a receptor for advanced-glycation (AGE) and lipoxidation end-products (ALE). Evidence indicates a significant upregulation in circulating levels and visceral adipose tissue production of Galectin-3 in obesity and type 2 diabetes. Recent studies demonstrate development of obesity and dysregulation of glucose metabolism in Galectin-3 “knockout” (KO) mice, which also develop accelerated and more severe pathology in models of atherosclerosis and metabolically-induced kidney damage. Thus, evidence that Galectin-3 is an important player in metabolic disease is accumulating. This review discusses current evidence on the connection between Galectin-3 and metabolic disease, focusing on mechanisms by which this galectin modulates adiposity, glucose metabolism and obesity-associated inflammatory responses.</jats:p> |
| container_issue |
4 |
| container_start_page |
273 |
| container_title |
Serbian Journal of Experimental and Clinical Research |
| container_volume |
16 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792332207917891595 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T13:53:13.086Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Galectin-3+In+Obesity+And+Type+2+Diabetes&rft.date=2015-12-01&genre=article&issn=2335-075X&volume=16&issue=4&spage=273&epage=280&pages=273-280&jtitle=Serbian+Journal+of+Experimental+and+Clinical+Research&atitle=Galectin-3+In+Obesity+And+Type+2+Diabetes&aulast=Pejnovic&aufirst=Nada&rft_id=info%3Adoi%2F10.1515%2Fsjecr-2015-0057&rft.language%5B0%5D=und |
| SOLR | |
| _version_ | 1792332207917891595 |
| author | Pejnovic, Nada |
| author_facet | Pejnovic, Nada, Pejnovic, Nada |
| author_sort | pejnovic, nada |
| container_issue | 4 |
| container_start_page | 273 |
| container_title | Serbian Journal of Experimental and Clinical Research |
| container_volume | 16 |
| description | <jats:title>Abstract</jats:title><jats:p>Galectin-3 is an important regulator of inflammation and acts as a receptor for advanced-glycation (AGE) and lipoxidation end-products (ALE). Evidence indicates a significant upregulation in circulating levels and visceral adipose tissue production of Galectin-3 in obesity and type 2 diabetes. Recent studies demonstrate development of obesity and dysregulation of glucose metabolism in Galectin-3 “knockout” (KO) mice, which also develop accelerated and more severe pathology in models of atherosclerosis and metabolically-induced kidney damage. Thus, evidence that Galectin-3 is an important player in metabolic disease is accumulating. This review discusses current evidence on the connection between Galectin-3 and metabolic disease, focusing on mechanisms by which this galectin modulates adiposity, glucose metabolism and obesity-associated inflammatory responses.</jats:p> |
| doi_str_mv | 10.1515/sjecr-2015-0057 |
| facet_avail | Online, Free |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTUxNS9zamVjci0yMDE1LTAwNTc |
| imprint | Walter de Gruyter GmbH, 2015 |
| imprint_str_mv | Walter de Gruyter GmbH, 2015 |
| institution | DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229 |
| issn | 1820-8665, 2335-075X |
| issn_str_mv | 1820-8665, 2335-075X |
| language | Undetermined |
| last_indexed | 2024-03-01T13:53:13.086Z |
| match_str | pejnovic2015galectin3inobesityandtype2diabetes |
| mega_collection | Walter de Gruyter GmbH (CrossRef) |
| physical | 273-280 |
| publishDate | 2015 |
| publishDateSort | 2015 |
| publisher | Walter de Gruyter GmbH |
| record_format | ai |
| recordtype | ai |
| series | Serbian Journal of Experimental and Clinical Research |
| source_id | 49 |
| spelling | Pejnovic, Nada 1820-8665 2335-075X Walter de Gruyter GmbH General Medicine http://dx.doi.org/10.1515/sjecr-2015-0057 <jats:title>Abstract</jats:title><jats:p>Galectin-3 is an important regulator of inflammation and acts as a receptor for advanced-glycation (AGE) and lipoxidation end-products (ALE). Evidence indicates a significant upregulation in circulating levels and visceral adipose tissue production of Galectin-3 in obesity and type 2 diabetes. Recent studies demonstrate development of obesity and dysregulation of glucose metabolism in Galectin-3 “knockout” (KO) mice, which also develop accelerated and more severe pathology in models of atherosclerosis and metabolically-induced kidney damage. Thus, evidence that Galectin-3 is an important player in metabolic disease is accumulating. This review discusses current evidence on the connection between Galectin-3 and metabolic disease, focusing on mechanisms by which this galectin modulates adiposity, glucose metabolism and obesity-associated inflammatory responses.</jats:p> Galectin-3 In Obesity And Type 2 Diabetes Serbian Journal of Experimental and Clinical Research |
| spellingShingle | Pejnovic, Nada, Serbian Journal of Experimental and Clinical Research, Galectin-3 In Obesity And Type 2 Diabetes, General Medicine |
| title | Galectin-3 In Obesity And Type 2 Diabetes |
| title_full | Galectin-3 In Obesity And Type 2 Diabetes |
| title_fullStr | Galectin-3 In Obesity And Type 2 Diabetes |
| title_full_unstemmed | Galectin-3 In Obesity And Type 2 Diabetes |
| title_short | Galectin-3 In Obesity And Type 2 Diabetes |
| title_sort | galectin-3 in obesity and type 2 diabetes |
| title_unstemmed | Galectin-3 In Obesity And Type 2 Diabetes |
| topic | General Medicine |
| url | http://dx.doi.org/10.1515/sjecr-2015-0057 |